GNS LSE Week ended 07 Aug 2026

Weekly Investor Report

Genus plc · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 2,304 GBP
5.0% latest week
Weekly setup

Mixed setup

The weekly trend is not active. Price is -7.9% below the Trend Line and sits at 28.1% of its 52-week range. The latest completed week returned 5.0%, after a 14.1% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks strongly; valuation is expensive relative to peers. The latest news-sentiment score is 56/100.

Setup score 37 out of 100
Latest Close 2,304 GBP 7 Aug 2026
1W Return 5.0% latest completed week
4W Return 14.1% short-term follow-through
12W Return -4.1% quarterly tape
Trend Breadth 61.5% 32 of 52 weeks active
Volume Ratio 1.0x vs 13-week average
What is working
  • Price is above Fair Value, showing premium demand versus the model.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Activity pressure is negative, which weakens the current setup.
  • Activity pressure is weak, so confirmation is not yet broad enough.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 5.0% Latest completed week; four-week move 14.1%. Indicator stack 34/48 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. News sentiment 56/100 17 relevant articles in the latest sentiment read.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -7.9% below the Trend Line and sits at 28.1% of its 52-week range. The latest completed week returned 5.0%, after a 14.1% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 1.0x the 13-week average. Participation is around or above normal and provides reasonable confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul 7 Aug
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.0712-week average 0.11

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.07Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 14.1% over four weeks, -4.1% over 12 weeks, and -7.5% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W5.0%
4W14.1%
12W-4.1%
26W-27.1%
52W-7.5%
Active trend streak0 weeks
Active weeks in one year32
Trend breadth61.5%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-0.40Latest activity-pressure read.
Pressure change67.8%Four-week change in activity pressure.
Leadership-16.02Latest relative-leadership reading.
RS change35.8%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks strongly; valuation is expensive relative to peers.

Open full factor analysis
Factor week 09 Aug 2026 Financial statements through 31 Dec 2025 Field coverage 88% Model confidence 70%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength1/100Blend of value, momentum, and quality. Underlying universe rank 100; rank 1 is best.
Value3/100Relative valuation strength. Underlying universe rank 98; rank 1 is best.
Quality13/100Profitability and accounting quality. Underlying universe rank 88; rank 1 is best.
Momentum9/100Medium-term price momentum. Underlying universe rank 92; rank 1 is best.
Growth87/100Revenue and earnings growth. Underlying universe rank 14; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Value-quality framework9/100Value and quality alignment from the Sharemaestro SVQF framework.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
79.3x
Price divided by trailing earnings.
Price / sales
2.3x
Market value relative to trailing revenue.
EV / EBITDA
18.8x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
2.8%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-
Gross profit retained from each unit of revenue.
Operating margin
6.3%
Operating profit retained from revenue.
Free-cash-flow margin
7.2%
Free cash flow generated from revenue.
Return on invested capital
4.4%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
0.6%
Latest one-year revenue growth.
EPS growth
144.3%
Latest one-year earnings-per-share growth.
Free-cash-flow growth
852.9%
Latest one-year free-cash-flow growth.
Piotroski F-score
7/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
1.4%
Cash dividends relative to market value.
Buyback yield
0.0%
Net share repurchases relative to market value.
Shareholder yield
1.4%
Dividend yield plus net buyback yield.
Net debt / EBITDA
2.3x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment56/100

Weighted news tone is neutral across 17 relevant articles.

4 positive · 13 neutral · 0 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-28.6%Distance below the 52-week high.
13-week volatility5.0%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher12 of 2614 weeks finished lower.
Best week+6.1%Week of 3 Jul.
Worst week-11.8%Week of 10 Jul.
Latest week+5.0%Week of 7 Aug.

Shape of recent returns

Strong gains4
Modest gains8
Flat weeks0
Modest losses6
Sharp losses8
Recent vol5.0%13-week weekly-return volatility.
Base vol5.1%52-week weekly-return volatility.
Up/down split26/26Count of positive and negative weeks in the 52-week window.
Average skew4.0% / -4.1%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape32/100

Trend, activity pressure, participation, and risk combine to a 32/100 tape read.

 Indicator analysis10/100

Latest 12-week confirmation: trend 0/12, activity pressure 0/12, relative leadership 0/12.

Activity pressure 0.07; No reversal markers Factors5/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 75; Small Cap Core rank 95 SVQF9/100

Value and quality alignment from the Sharemaestro SVQF framework.

Composite rank 236.0 of 260 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment56/100

Weighted news tone is neutral across 17 relevant articles.

How Is Genus (LSE:GNS) Navigating a Fast-Moving UK Stock-Market Theme? Insiders50/100

No recent insider transaction evidence is stored.

 Earnings50/100

No stored earnings event is currently attached to this ticker.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
7 Aug 20262,304 GBP5.0%2,502 GBP2,131 GBP-0.40-16.02698.7KOff
31 Jul 20262,194 GBP2.7%2,510 GBP2,131 GBP-0.73-20.17814.1KOff
24 Jul 20262,136 GBP0.3%2,522 GBP2,133 GBP-0.87-21.741.4MOff
17 Jul 20262,130 GBP5.4%2,536 GBP2,135 GBP-1.05-21.371.7MOff
10 Jul 20262,020 GBP-11.8%2,548 GBP2,137 GBP-1.25-24.961.4MOff
3 Jul 20262,290 GBP6.1%2,567 GBP2,138 GBP-1.41-16.6873.4KOff
26 Jun 20262,158 GBP-2.2%2,579 GBP2,138 GBP-1.55-20.3150.9KOff
19 Jun 20262,206 GBP1.1%2,589 GBP2,138 GBP-1.47-17.51391.7KOff
12 Jun 20262,182 GBP-4.0%2,597 GBP2,140 GBP-1.34-19.3273.9KOff
5 Jun 20262,274 GBP-2.3%2,603 GBP2,142 GBP-1.19-15.1961.7KOff
29 May 20262,328 GBP-6.1%2,609 GBP2,143 GBP-1.10-13.58667.4KOff
22 May 20262,478 GBP3.2%2,616 GBP2,144 GBP-0.97-8.58558.6KOff
15 May 20262,402 GBP3.5%2,624 GBP2,145 GBP-0.92-9.06968.6KOff
8 May 20262,320 GBP-1.5%2,629 GBP2,146 GBP-0.81-12.56938.2KOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.

Evidence context